A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

NCT04740671 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

410

Enrollment

INDUSTRY

Sponsor class

Conditions

Age Related Macular Degeneration

Interventions

DRUG: HLX04-O
DRUG: ranibizumab

Sponsor

Shanghai Henlius Biotech